Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: Retrospective claims database analysis

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 2081-2090

  Mei, Sheng Duh ^a   Dial, Ellison ^a   Choueiri, Toni K ^b   Fournier, Andree Anne ^a   Antras, Lucia ^a   Rodermund, Douglas ^a   Neary, Maureen P ^c   Oh, William K ^b  

^a ANALYSIS GROUP   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Angiogenesis inhibitors; Cost; IV bevacizumab; Renal cell carcinoma

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; INFECTION RISK; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; OUTPATIENT CARE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; AGED; ANGIOGENESIS INHIBITORS; DATABASES AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 67651006619     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903084800     Document Type: Article

References (24)

1. Cancer Facts and Figures 2008. American Cancer Society. Atlanta, GA: American Cancer Society, 2008. Available at: http://www.cancer.org/downloads/ STT/2008CAFFfinalsecured.pdf [Last accessed: 10 September 2008]
2. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31
3. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986;136:376-9
4. Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125-44
5. Curti BD. Renal cell carcinoma. JAMA 2004;292:97-100
6. Menzel T, Bergmann L. Treatment strategies in metastatic renal cell carcinoma. Onkologie 1999;22:472-6
7. Nexavar (sorafenib) Full Prescribing Information. Bayer HealthCare. Available at: http://berlex.bayerhealthcare.com/html/products/pi/Nexavar-PI.pdf [Last accessed: 17 November 2008]
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell-renal-cell carcinoma. N Engl J Med 2007;356:125-34
9. Mulder SF, van Spronsen DJ, De Mulder PH. Do the results of the new trials change the standard treatment of metastatic renal cell cancer? Onkologie 2007;30:260-4
10. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-73
11. Sutent (sunitinib malate) U.S. Physician Prescribing Information. Pfizer. Available at: http://media.pfizer.com/files/products/uspi-sutent.pdf [Last accessed on 17 November 2008]
12. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24
13. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24
14. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
15. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11
16. Avastin (bevacizumab) Full Prescribing Information. Genentech. Available at: http://www.gene.com/gene/products/information/oncology/avastin/insert.jsp [Last accessed: 17 November 2008]
17. DeMario MD, Ratain, MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557-67
18. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007;64:S4-7
19. SEER Stat Fact Sheets; Cancer: Kidney and Renal Pelvis. Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/statfacts/ html/kidrp.html [Last accessed 17 November 2008]
20. Bukowski RM, Kabbinavar FF, Figlin, RA. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536-41
21. NCCN Clinical Practice Guidelines in Oncology; Kidney Cancer, V.1.2009. National Comprehensive Cancer Network
22. Ljungberg B, Hanbury DC, Kucyk AS, et al. Guidelines on renal cell carcinoma. European Association of Urology, 2007
23. Rini BI, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress? Oncology 2008;22:388-480
24. Duh MS, Weiner JR, Lefebvre P, et al. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. Curr Med Res Opin 2008;24:967-7